CSF1R inhibitors have attracted great interest as promising therapeutic agents, particularly in cancer, mostly because of their ability to modulate tumor‐associated macrophages, which typically present an immunosuppressive phenotype that aids tumor progression (Lv et al., 2024; Mok et al., 2014; Strachan et al., 2013; Xu et al., 2013). This evidence concerns the gene CSF1R and neoplasm.